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Kinetic parameters of human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) infections
have been estimated from plasma virus levels following perturbation of the chronically infected (quasi-) steady
state. We extend previous models by also considering the large pool of virus localized in the lymphoid tissue
(LT) compartment. The results indicate that the fastest time scale of HIV-1 plasma load decay during therapy
probably reflects the clearance rate of LT virus and not, as previously supposed, the clearance rate of virus in
plasma. This resolves the discrepancy between the clearance rate estimates during therapy and those based on
plasma apheresis experiments. In the extended models plasma apheresis measurements are indeed expected
to reflect the plasma decay rate. We can reconcile all current HIV-1 estimates with this model when, on average,
the clearance rate of virus in plasma is approximately 20 day21, that of LT virus is approximately 3 day21, and
the death rate of virus-producing cells is approximately 0.5 day21. The fast clearance in the LT compartment
increases current estimates for total daily virus production. Because HCV is produced in the liver, we let virus
be produced into the blood compartment of our model. The results suggest that extending current HCV models
with an LT compartment is not likely to affect current estimates for kinetic parameters and virus production.
Estimates for treatment efficacy might be affected, however.
Our understanding of the dynamics of human immunodefi-
ciency virus type 1 (HIV-1) infection relies largely on the
analysis of changes in the viral load in plasma after initiation of
treatment with potent antiretroviral drugs. Quantitative math-
ematical models have been fitted to clinical data to provide
estimates for the virion clearance rate, the average life span of
productively infected cells, the viral generation time, and the
total daily production of virus (14, 15, 20, 21). These studies
have identified two time scales during the first 1 to 2 weeks of
potent antiviral therapy. The slower of the two was supposed to
reflect the turnover of virus-producing cells, with an average
death rate (d) of about 0.5 day21. For the faster decay of virus
particles a “clearance” rate (c) of about 3 day21 was found.
The estimation of c from the total virus decline was later
suggested to be unreliable (7), but an independent measure-
ment of the decline of plasma infectivity (21) supported the
estimate of .3 day21.
A recent plasma apheresis study yielded significantly faster
estimates for the HIV-1 virus clearance (22). Large quantities
of plasma were removed from infected patients to create an
additional clearance term for the virus. During the 1 to 2 h of
apheresis, the virus level in plasma dropped significantly and
rapidly returned to baseline levels after the apheresis was
stopped. A mathematical model was fitted to the data to obtain
estimates for the natural clarance rate c. The estimates for four
patients ranged from 9 to 36 day21, with an average of approx-
imately 23 day21. Although the early estimates of approxi-
mately 3 day21 were established as lower bounds, we show
below that the large discrepancy in the estimates for c can be
due to the compartmentalization of the virus pool. The esti-
mates for the turnover rate, d, of virus-producing cells have
also been published as lower bounds (21) and have also been
questioned (5). In HIV-1-infected patients, no correlation be-
tween d and the magnitude of the cytotoxic response was found
(17). This resulted in a debate on the importance of the cyto-
toxic immune response (4) and in more sophisticated immune
control models (13).
It has long been known that the major site of HIV-1 infec-
tion is the lymphoid tissue (LT) (3, 19). The trafficking of
lymphocytes between the plasma and the LT compartment has
been shown to be of potential importance in HIV-1 infection
(12, 23). Here we extend this approach to the distribution of
virus. A series of studies have confirmed that most of the virus,
i.e., on the order of 1010 virions in a typical patient, resides in
the LT compartment (1, 6, 18, 24). Most of the virus is bound
to the surfaces of follicular dendritic cells (FDCs). Surpris-
ingly, virus in the LT was found to decline at about the same
rate as free virus in plasma during therapy (1): during the first
two days of therapy, virus in LT declined at a rate of about 0.4
day21. Later the decay slows down, which may be due to
multivalent binding (9). The early parallel declines of virus in
LT and plasma suggest that on this time scale of a few days
there is a (quasi-) steady state between the two virus compart-
ments that is maintained by an exchange of viral particles. The
decay of virus in LT introduces a third time scale, which is
intermediate to those for c and d and which hence influences
the established estimates.
Mathematical analysis of plasma apheresis (22) and antiviral
treatment data (14) has also been carried out for hepatitis C
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virus (HCV). To explain the rapid drop of the viral load in
plasma in about 1 day, which is followed by a slower second-
phase decay, Neumann et al. suggested that alpha interferon
(IFN-a) blocks the production of new HCV virus particles
(14). The first-phase decay was dominated by a c of approxi-
mately 6 days21, and the slow second-phase decay, with 0.01
day21 , d , 0.4 day21 was conjectured to reflect the death
rate of virus-producing cells.
The HCV estimates from the plasma apheresis study are in
much better agreement with the treatment estimates: in two
patients virion clearance rates were estimated to be 5.5 and 9.9
day21. Below we suggest that the reason for this difference
between HIV-1 and HCV is the different localization of virus
production. Whereas HIV-1 is mostly produced in the LT,
HCV is produced in the liver, which connects to the blood
plasma compartment. By implementing this difference in the
models we are able to show that the impact of an LT virus
reservoir on turnover parameter estimates is likely to be much
smaller for HCV than for HIV-1. Total virus production esti-
mates are also more reliable.
MATERIALS AND METHODS
The models. The models consider virus-producing infected cells, I, free plasma
virus, VP, and virus in the lymphoid tissue, VL. To set the pretreatment steady
state, we write a simplified term allowing for limited target cell availability (see
Appendix). Thus, in the pretreatment situation new infections occur at a rate (b)
given by b 5 bmaxV/(h 1 V), where bmax is the maximum value of b and h is a
saturation parameter. Because we set bmax 5 0 during highly active antiretroviral
therapy (HAART), most results do not depend on the form of this equation.
Altenatively, we could have allowed for a density-dependent d to model an
immune response.
Virus is produced at rate p, with units of per infected cell per day, and is
cleared from the blood at rate c and from the LT at rate cL. Assuming a constant
immune response on the time scale of treatment, the death rate of infected cells,
d, is a fixed parameter. Between the two compartments there is an exchange of
virus at rates i, for influx into the blood, and e, for efflux from the blood into the
LT. Most of the virus in the LT is in fact bound onto FDCs. Because the kinetics
of virus association and dissociation seems to be fast (9), we treat LT virus as a
single population. Our LT clearance rate cL should therefore be interpreted as
an average over the bound and the free virus in the LT. In the Appendix we
briefly discuss how this simplification can be derived.
In the paper we consider “typical” patients with most of the virus in the LT,
i.e., VL .. VP, and “late-stage” patients with equal amounts of virus in the LT
and in the plasma. This difference is probably caused by the destruction of the
FDC network during disease progression, which reduces the amount of virus that
can be bound to FDCs (11). The LT virus population in our model is a mixture
of FDC-bound virus and free virus in the LT. Virus bound to FDCs with multiple
bonds is probably protected from fast clearance and has a longer residence time
in the LT than free virus (9). Destruction of the FDC network during disease
progression is therefore expected to increase cL and the rate of transport (i) of
our mixed-virus population in the LT to the plasma. In this paper we vary both
parameters to (i) model late-stage patients with high i and (ii) study the effect of
the unknown cL in the LT. Since the steady-state plasma viral load is propor-
tional to the amount of virus released from the LT into the plasma (see below),
increasing i decreased the VL/VP ratio.
In the HIV model virus-producing CD41 T cells reside in the LT. Conversely,
in the HCV model, where the infected cells are mostly hepatocytes, virus is
released into the blood plasma compartment. Thus for the HIV-1 model we write
dI
dt
5
bmax
h 1 VL
VL 2 dI (1)
dVL
dt
5 pI 1 eVP 2 ~i 1 cL!VL (2)
dVP
dt
5 iVL 2 ~e 1 c!VP (3)
whereas in the HCV model produced virus enters the blood so we write
dI
dt
5
bmax
h 1 VP
VP 2 dI (4)
dVL
dt
5 eVP 2 ~i 1 cL!VL (5)
dVP
dt
5 pI 1 iVL 2 ~e 1 c!VP (6)
Due to the density-dependent infection term, the nontrivial equilibrium of both
models is always stable.
We make a clear distinction between “true” virus clearance, cL and c, and the
“transport” terms, i and e: the “total clearance” rates are defined by cˆ [ e 1 c
and cL
Ù
[ i 1 cL. As there is no known biological mechanism that would transport
large amounts of virus from the blood to the LT, e should be small. The flux of
virus from the LT to the blood probably follows the flow of lymph to the blood.
Later we will show that the plasma apheresis experiments suggest that this
process is also likely to be slow, hence i should also be small. Because this flux is
not passive diffusion, we write the explicit flux parameters e and i and formulate
our system in terms of total body counts of productively infected cells, plasma
virions, and LT virions. By appropriate scaling one can, however, rewrite the
model in terms of concentrations and conventional diffusion-like transport terms.
During a treatment blocking new infections, we set b 5 0. As this makes the
model linear, one may solve the eigenvalues of the full system (equations 1 to 3)
to find that l1 5 2d and
l2,3 5
1
2 S2(cˆ 1 cLˆ) 6 (˛cˆ 2 cLˆ)2 1 4eiD (7)
We have argued above, and suggest below, that transport parameters e and i are
probably small. If the product ei is sufficiently small, i.e., if 4ei is ,,(cˆ 2 cL
Ù )2, one
obtains the simple eigenvalue structure l1 5 2d, l2 5 cL
Ù , and l3 5 cˆ, such that
the solution becomes
VP~t! 5
VP~0!
~cˆ 2 cLˆ!~cˆ 2 d!~cLˆ 2 d!
3 (8)
@@cˆcLˆ~cˆ 2 cLˆ!e2dt 1 cLˆd~cLˆ 2 d!e2cˆt 2 cˆd(cˆ 2 d)e2cLt
Ù
]
The kinetics of the viral load in the plasma, VP, thus has three time scales, set by
d, cˆ, and cL
Ù .
Plasma apheresis. The clearance rate of plasma virus has been studied with
plasma apheresis experiments (22). During plasma apheresis the removal of
plasma increases the clearance of free plasma virus. The changes in plasma virus
concentration were modeled by the equation
dVP
dt
5 P 2 c9VP (9)
where P is the total input of virus into the blood and c9 is the sum of the natural
clarance rate c and the rate of removal by apheresis, e . The input P represents
virus production and was considered to be constant during the 1 to 2 h of
apheresis. Estimates for c and P were obtained by a nonlinear fitting procedure
of the plasma virus concentrations before, during, and after apheresis. In total
less than 108 virus particles were removed during an experiment.
Although 108 particles correspond to a significant fraction of the total plasma
virus pool, VP, it is less than 1% of the total virus load, VP 1 VL. Thus, the mere
fact that one finds an observable decline in the plasma virus load by removing less
than 1% of the total body virus suggests that the exchange between the LT
compartment and the blood cannot be too rapid, i.e., transport rates i and e have
to be sufficiently small. In our two-compartment model the input term in equa-
tion 9 becomes P 5 iVL and the clearance term becomes c9 5 c 1 e 1 e . Because
typically VL is ..VP, it is reasonable to assume that P (5iVL) hardly varies during
the apheresis. Thus equation 9 applies equally well to our two-compartment
model for HIV-1, with the only change being that the estimated clearance rate of
23 day21 (22) should reflect the total clearance, cˆ 5 c 1 e.
For HCV, the input of free plasma virus is production plus influx from the LT
(see equation 6), i.e., P 5 pI 1 iVL, which can again be treated as constant during
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plasma apheresis. The clearance rate in equation 9 remains c9 5 c 1 e 1 e . Thus,
the plasma apheresis estimates for the total clearance, cˆ 5 c 1 e, are 5.5 and 9.9
day21 (22). These estimates are close to those obtained from treatment of
HCV-infected patients, which suggested a cˆ of 6 day21 (14).
Because the transport rate of virus from the plasma to the LT is probably small
and because the plasma apheresis experiments suggest a limited exchange on a
time scale of hours, we will assume that the efflux rate, e, is small, i.e., we set e 5
1 day21 for both viruses. This seems a conservative choice because the rapid total
clearance rates measured during the plasma apheresis experiments would largely
reflect the true clearance, c (22). Accordingly, we set c at 24 day21 for HIV-1 and
7 day21 for HCV. For robustness all simulations were checked for a c of 5 day21
and an e of 20 day21 for HIV-1 and for a c of 2 day21 and an e of 6 day21 for
HCV.
RESULTS
Antiviral treatment: HIV-1. (i) The 1- to 2-week time scale of
total virus decline. Combination therapy of HIV-1 infection
with protease and reverse transcriptase inhibitors blocks new
infections and renders newly produced virus noninfectious. As
a consequence, the population of virus-producing cells declines
exponentially at rate d (10). After a fast initial transient dom-
inated by the fast clearance of plasma virus, the decline of the
plasma virus load was believed to approach the same slope, d
(21). In models allowing for additional virus compartments,
such as LT, this need not remain true. Assuming for simplicity
a 100% drug efficacy and considering the total virus load (i.e.,
infectious plus noninfectious virus), we model similar treat-
ment by setting the maximum infection rate bmax 5 0.
To study how the different compartments affect the estimate
of d, we first ignore the fast transient by a quasi-steady-state
(QSS) assumption for the plasma virus, VP 5 iVL/cˆ. Solving the
QSS model for bmax 5 0, one obtains for the LT virus
VL~t! 5
VL~0!
d 2 g
~de2gt 2 ge2dt! (10)
where
g ; cL 1 c
VP~0!
VL~0!
with
VP~0!
VL~0!
5
i
e 1 c (11)
Because of the QSS assumption the plasma virus load remains
proportional to equation 10. The two different true clearance
rates, cL and c, of virus turnover are combined into a compos-
ite decay rate, g. Note that for the supposedly small value of e,
g . cL
Ù . After a fast initial transient, the behavior of the system
will be dominated by the slowest exponent in equation 10,
i.e., by g or d. Thus, the observed slope at which virus
declines in the blood will not reflect the death rate, d, of
productively infected cells whenever g is ,d. This we call
the “masking” of infected-cell turnover rates. In equations
11 g can only be smaller than d under the following condi-
tion: cL 1 ci/(e 1 c) . cL 1 i 5 cL , d. To remain consistent
with the data (10, 21), the slower of the two exponents should
be about 0.5 day21. We therefore set d 5 1 day21 and we
restrict ourselves to values of cL
Ù
$0.5 day21. When the FDC
network is degraded during disease progression, one may ex-
pect the flow rate, i, of virus from the LT to the blood to
increase because a smaller fraction of the LT virus is bound to
the FDCs (11). In terms of equations 11, disease progression is
thus expected to increase g and the VP/VL ratio.
We studied the full model numerically to find parameter
values that are consistent with the treatment and the plasma
apheresis estimates and to investigate when we find masking
(i.e., g , d). In all numerical examples we found similar be-
havior for the QSS model and the full system, confirming the
validity of equation 10. Typically, in asymptomatic patients one
finds that most of the total body virus is confined to the LT (6,
18). A patient with a QSS I of 108 virus-producing cells and VP
of 108 plasma virus particles might harbor as many as 5 3 1010
virus particles in the LT (6). The first 10 day of the treatment
of such a patient is depicted in Fig. 1a, where we first set 0.5
day21 for the decay rate of LT virus. All other parameter
values are set such as to obtain the required initial steady state
(Fig. 1). Because VL is ..VP, we find that g is ,d in this
example, and the observed decline of the plasma virus load is
dominated by the decay rate, cL
Ù , of LT virus and not by the
death rate, d, of virus-producing cells. This provides an exam-
ple of the masking of d.
FIG. 1. Viral load during HAART as obtained by equations 1 to 3. (a and c) Typical situation with a large LT virus compartment (VL .. VP)
for slow and rapid LT clearance rates, respectively. (b) Late-stage patient, with equal amounts of virus in the LT and blood compartment and a
slow LT clearance rate. In panel a there is masking of d, whereas in panels b and c the plasma viral load is coming down at rate d. Parameters:
c 5 24 day21, e 5 1 day21, d 5 1 day21, and h 5 109. We set bmax 5 1.02 3 10
8 to attain the stable pretreatment equilibrium and set bmax 5 0
at day 0. Other parameters are as follows: i, 0.05 (a and c) and 25 day21 (b); cL, 0.5 (a and b) and 5 day
21 (c); p, 274 (a and b) and 2,524 particles
cell21 day21 (c). Initial steady state, VL 5 5 3 10
10 particles, Vp 5 10
8 particles, I 5 108 cells (a and c) and VL 5 1.4 3 10
8 particles, VP 5 1.4 3
108 particles, I 5 1.3 3 107 cells (b).
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Because patients in a more-advanced stage of the disease
can have a much smaller compartment of LT virus (11), our
next example is a case with equal amounts of virus in the blood
and in the LT. To achieve VL 5 VP, we increased the influx
rate, i, of virions from LT to blood 500-fold. All other param-
eter values were unchanged. The time course of treatment is
depicted in Fig. 1b. The decline of virus compartments ap-
proaches that for the productively infected cells (d) (the graphs
of VL and VP coincide with the graph depicting d). In this case
g is .d, and indeed there is no masking. Because c is .d, such
a situation is expected when a sufficiently large fraction of the
total-body virus is located in the blood (see equations 11).
The turnover rate of LT virus is unknown and need not be a
simple exponential decline (9). Equation 10 only shows that
the slower of the g and d timescales is reflected in the parallel
declines of plasma and LT virus. Figure 1c depicts the same
system also for a 10-fold-higher clearance of LT virus. To allow
for the same initial steady state, we compensated by changing
the production rate accordingly (Fig. 1c). Because g is .d in
Fig. 1c, d masks cL, and a realistic d of 1 day
21 is observed. The
latter scenario implies a rapid clearance of virus from the LT,
i.e., implies that cL
Ù is .d.
Summarizing, for cases representing typical asymptomatic
patients where VL is ..VP, there are two parameter settings
that remain consistent with the previous observations (10, 21,
22). First, the turnover of LT virus may be slow, i.e., cL
Ù . 0.5
day21, and would be expected to be responsible for the ob-
served decline of virus in the blood. Second, the turnover of LT
virus may be fast, i.e., cL
Ù
. d, such that the observed decline of
virus in the blood reflects the turnover, d, of productively
infected cells. In the first scenario LT virus turnover masks d,
whereas in the second d masks LT virus turnover. Finally,
because the masking in the slow-turnover scenario depends on
the VL/VP ratio, it may depend on disease stage. Such a de-
pendence is not expected for the rapid-turnover scenario.
(ii) The rapid time scale of infectious virus. During com-
plete protease inhibitor treatment the infectious virus titer was
expected to fall with a slope of c (21). Data from a single
late-stage patient revealed that this slope was approximately
3 day21 (21). For the same patient d was estimated to be 0.53
day21. Considering the infectious virus titer only, we modeled
complete protease inhibitor treatment by setting p 5 0. As-
suming, as above, that the product of the transport parameters,
ei, is sufficiently small, we obtain
VP~t! .
VP~0!
cˆ 2 cLˆ
~cˆe2cLˆt 2 cLˆe2cˆt! (12)
with cL
Ù and cˆ time scales. Since, the turnover rate, cL
Ù , of the LT
virus has the slower time scale, it is expected to dominate the
dynamics. In Fig. 2 we consider the full model with p 5 0 for
same three cases as in Fig. 1. Indeed we see that the decay rate
of LT virus dominates, and that it masks clearance rate cˆ in the
blood, in Fig. 2a and c, representing typical patients with VL ..
VP (i.e., small i). The observed slope of 3 day
21 (21) could
therefore correspond to the total clearance, cL
Ù , of LT virus. To
model the late-stage patient of Fig. 2b, with VL 5 VP, we
increased the rate of transport, i, of virus from the LT to the
plasma. Increasing i increases cL
Ù , such that cˆ may come to
represent the slower time scale. Indeed in Fig. 2b we observe
a rapid slope of approximately 24 day21.
(iii) Interpretation. The dynamics of plasma virus is charac-
terized by three time scales, each of which can be estimated
from existing data sets. Plasma apheresis (22) provides an
estimate of approximately 23 day21 for the total clearance of
plasma virus. For patients with a large LT virus pool, the
observed decline of infectious virus at rates of at least 3 day21
(21) should reflect the slower of clearance rates cˆ, and cL
Ù ,
which is then necessarily the latter. Total plasma virus and LT
virus decline at a rate of 0.5 day21 (10), which in typical
patients with VL .. VP should be dominated by the slower of
cL
Ù and d, which would then be d. Hence the model is consistent
with current data when cˆ is .23 per day, cL
Ù is .3 per day, and
d is .0.5 per day.
HCV. The biphasic decline of plasma virus titers during
IFN-a treatment of HCV infection suggests that the inhibition
of virus production is incomplete and that the second-phase
slope reflects the decline of residual production by the death
rate, d, of virus-producing cells (14). This was modeled by
decreasing virus production by factor e . Because we cannot set
b 5 bmax 5 0 during IFN-a treatment, we fixed the infection
FIG. 2. Blocking viral production in HIV-1 infection. The plasma virus titer follows the decay rate of LT virus if the LT reservoir is large (a
and c) and follows the decay rate of plasma virus if it is small (b). The parameters and initial steady states are the same as in the corresponding
panels of Fig. 1. Treatment is modeled by setting p 5 0.
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rate, b, at its pretreatment value to keep it constant on the
short time scale of interest. For the plasma viral load we obtain
dVP
dt 5 ~1 2 e !pI 1 iVL 2 ~e 1 c!VP (13)
For HCV the typical total blood pool of virus is on the order
of 1010 particles and the size of the LT virus compartment is
unknown. We investigated two scenarios, one with a large LT
virus compartment and one with an LT virus compartment
equal to the blood compartment. Obviously, when the LT virus
compartment is sufficiently small, it will fail to affect the be-
havior of the new model. In “Plasma apheresis” we suggested
setting cˆ 5 8 day21; hence we set e 5 1 day21 and c 5 7 day21.
The fast initial drop of viremia does not allow for a much
smaller true clearance rate, c (not shown), which further con-
firms the assumption of a small efflux, e. We set d 5 0.5 day21
and VP(0) 5 10
10 particles, while the remaining free param-
eters, i.e., p, b, and i, were set so as to obtain the required
pretreatment steady state. Figure 3 shows different drug effi-
cacies (i.e., e 5 0.99 and 0.80 [14]), depicting the slopes of the
three decay rates and the total body count of plasma and LT
virus. For comparison with the model of Neumann et al. (14),
Fig. 3 also depicts the solution of their one-compartment
model.
For Fig. 3a and b where VL(0) 5 10VP(0), we have to allow
for a small decay rate of LT virus, e.g., cL 5 0.05 day
21. This
constraint stems from the pretreatment ratio of the two virus
pools, i.e., VL/VP 5 e/cL
Ù . As in the original model (14), the
decline of plasma virus is biphasic (Fig. 3). The two models
agree on the rapid first phase, which fits well to a slope of cˆ.
Thus, no masking is expected for the decay rate of plasma
virus. The models differ with respect to the second-phase de-
cay, however. When the LT virus compartment is large, the
kinetics of the two-compartment model is significantly slower
than that of the earlier model. In this case a slow decay of LT
virus may mask d. The masked death rate could be even higher
than the 0.5 day21 in our example. Thus, if the two-compart-
ment model reflects reality better, the death rate of virus-
producing cells could be much larger than the previous esti-
mates (14). Additionally, the depth of the drop in the virus
load during the rapid first phase is significantly smaller in the
two-compartment model than it is in the previous model. Since
this initial drop of viremia was used to assess the efficacy of the
IFN-a treatment, the drug efficacy, e , could also be an under-
estimate. Note that this effect is strongest at high efficacy (cf.
Fig. 3a and b).
Figure 3c and d depict the situation with equally large virus
compartments. Although for both phases the slopes are in a
fairly good agreement with those of the original model, the
second-phase decline of plasma viremia reflects an intermedi-
ate rate between d and cL
Ù . In the two-compartment model, the
initial drop of plasma viremia remains small, however. To
obtain equal pool sizes, we increased the influx, i, of virus from
the LT compartment into the blood. This situation also allows
us to study higher LT virus decay rates. Increasing the decay
rate to 0.5 day21 had little effect on the difference in the initial
drop in the viremia (not shown). For even smaller LT com-
partment sizes, the masking effect of cL disappears altogether.
Summarizing, the two models always agree on the estimates
for cˆ during the initial phase. They differ in the estimation of
treatment efficacy. Whenever the LT compartment is suffi-
ciently large, they also differ in the estimate for d. This inter-
pretation is consistent with the observation that the HCV es-
timates for cˆ from the IFN-a treatment and the plasma
apheresis experiments were in good agreement (14, 22).
DISCUSSION
During asymptomatic HIV-1 infection the LT virus compart-
ment is known to be large. We have investigated how this LT
compartment may affect current procedures for estimating the
virus clearance rate, c, and the average lifetime of productively
infected cells, 1/d. We have found good agreement between all
previous studies when the total clearance rate in the blood, cˆ,
is .23 day21, the total clearance rate in the LT, cL
Ù (5cL 1 i)
is .3 day21, and d is .0.5 day21. As virus infusion experiments
suggest a relatively slow efflux from the blood, the true clear-
ance rate might be close to the above estimate, i.e., c . 20
day21. The dominance of the LT virus compartment in turn
requires a small influx rate, which implies that cL is .3 day
21.
Our results suggest that the LT total clearance rate, cL
Ù , and the
FIG. 3. HCV treatment dynamics where treatment blocks 99 (a and c) or 80% (b and d) of virus production. The initial decline reflects cˆ, the
total viral clearance in the blood. In panels a and b the LT virus compartment is large and the second-phase decline of plasma virus (heavy solid
line) follows the total plasma LT clearance rate, cL
Ù
. In panels c and d the plasma and the LT virus compartments are of equal size, and the rate
of the second-phase decline is between cL
Ù
and d. Symbols are as in Fig. 1. Heavy dash-dotted line, behavior of the original one-compartment model
(14). Parameters: c, 7 day21, e, 1 day21; d, 0.5 day21; cL, 0.05 day
21; i, 0.05 (a and b) and 0.95 day21 (c and d). The pretreatment plasma viral load
is identical in all panels (VP 5 10
10 particles), which was achieved by setting b and p. The initial total body counts of LT virus are 1011 particles
(a and b) and 1010 particles (c and d).
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total plasma clearance rate, cˆ, can be estimated from the deline
of infectious virus (21) and by plasma apheresis (22), respective-
ly. The death rate of virus-producing cells, d, can indeed (10,
21) be obtained from the decline of total plasma or LT virus.
Importantly, when the LT virus compartment is large, the
influx rate, i, has to be small and the decline of infectious virus
follows the LT clearance rate, cL (which was found to be 3 per
day in the single studied case [21]). This implies high estimates
for the total daily production of HIV-1 particles. An infection
involving a total body burden of 5 3 1010 particles would
require a production of at least 1.5 3 1011 particles per day.
Late-stage patients, having a smaller LT virus compartment
(11), would require a lower daily production.
We let virus production in HCV infection take place in the
blood compartment because the liver releases virus into the
blood. As yet, there are no good estimates available for the LT
virus compartment in HCV infection. Irrespective of its size,
however, allowing for a LT virus compartment hardly affects
current estimates for the total viral clearance rate, cˆ. Indeed,
the HCV estimates for cˆ obtained from plasma apheresis (22)
are in good agreement with those obtained from IFN-a treat-
ment (14). Because HCV production takes place in the blood
compartment, we can only have a large LT virus compartment
in our model by allowing for a very slow clearance rate, cL, in
the LT and a slow influx into blood. If our HIV-1 estimate of
cL
Ù . 3 day21 also holds for HCV, we would expect much a
smaller pool of LT virus in hepatitis infections. This implies
that current estimates of d (14) are not likely to be confounded
by the LT virus compartment and that the high plasma viral
loads associated with hepatitis B virus and HCV (14, 16) need
not reflect a much higher total body viral burden or production
than that estimated for HIV-1. The LT virus compartment may
nevertheless remain responsible for an underestimation of the
efficacy of IFN-a treatment.
The current model allowing for three time scales is still
lacking the possibly important slow time scale of virus attached
to the FDC network by multiple bonds (8, 9). Our QSS as-
sumption for virus bound to the FDC network is expected to be
valid during the first few day of treatment only. To reliably
study the later stages, one would have to merge the current
model with that of Hlavacek et al. (8, 9). Their work incorpo-
rates multiply bound virus particles but neglects the breakdown
of FDC-associated virus and does not account for the observed
rapid initial decline of plasma infectivity.
Another simplification of our model is the omission of virus
production by infected cells in the blood compartment. In our
typical patient, about 2.5 3 109 virions must enter the plasma
per day to balance the rate of loss observed in the plasma
apheresis experiments. With the most likely parameter setting
of Fig. 1c, this could be achieved by production from about 106
productively infected cells, i.e., 1% of the number present in
LT. This is close to the ratio of total CD4 T cells in blood to
CD4 T cells in LT. Even though infection is likely to induce
cells to home to lymph nodes (2), the contribution of blood
resident cells cannot be excluded completely. However, the
results of the present work are not affected by this possibility.
The behavior of the large LT virus pool during the first day of
HAART is hardly affected by the plasma pool. Hence our first
result remains valid: the 0.5-per-day decay rate of LT virus is
the slower of d and cL
Ù . Nor is the decline of plasma infectivity
affected, as the production of infectious virions is blocked both
in the plasma and in LT. This decline of 3 per day therefore
also remains the slower of cˆ and cˆL. As the estimates obtained
by plasma apheresis reflect cˆ, irrespective of the source term of
plasma virus, our interpretation remains valid for all three time
scales. Virus production in the blood might only affect the
short initial transient of total plasma virus, which is hard to
analyze due to the confounding effect of pharmaceutical delay.
In all, production of virus in the blood cannot be excluded by
our analysis but does not affect our results.
To summarize, the presence of an LT virus compartment in
current models of viral infection may confound parameter
estimation. Current data (1, 21) suggest that the average total
clearance rate cL
Ù , of virus in the LT compartment is relatively
fast. We can reconcile most data when the following relation
exists: cˆ . cL
Ù . 3 . d. Such a fast LT clearance implies that
current estimates of cˆ from plasma apheresis and of d from
antiviral treatment are hardly confounded by the LT virus
compartment and that virus production during HIV-1 infection
is even higher than was estimated previously. Finally, an LT
clearance rate of approximately 3 day21 would reconcile the
difference between the estimates for the plasma virus clearance
as obtained by plasma apheresis and HAART.
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APPENDIX
A standard equation for simple target cell dynamics is dT/dt 5 s 2
dTT 2 b*TV, where susceptible target cells, T, arise at rate s, die at
rate dT, and are infected at rate b*. For the pretreatment steady state
one sets dT/dt 5 0 to obtain T(0) 5
s
dT 1 b*V
. Substituting this into
infection term bTV, one obtains bmaxV/(h 1 V), where bmax 5 s and
h 5 dT/b*.
Virus in the LT is either free or bound to FDCs. As exchange with
the blood involves free virus only and binding to FDCs is reversible, we
write for the HIV-1 model VL 5 V*L 1 B and
dV*L
dt
5 pI 2 cLV*L 2 i*V*L 1 eVP 2 k1V*L 1 k2B (A1)
dB
dT
5 k1V*L 2 k2B 2 cLB (A2)
where V*L is free virus, B is bound LT virus, i* is the influx rate of
free LT virus into the blood, and k1 and k2 are association and
dissociation rates, respectively. k2 for monovalent binding was es-
timated as 0.1 per s (9), which is orders of magnitude faster than the
other processes in the system. As the association and dissociation of
virus mostly involve virions attached to FDCs by one or a few
ligands, one expects this fraction of bound virus to remain at QSS
with free virus. Setting dB/dt 5 0 one obtains B 5 k1V*L/(k2 1 cL).
Adding equation A2 to equation A1 one obtains equation 2 with
i 5 i*
k2 1 cL
k1 1 k2 1 cL
.
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